Hikma Pharmaceuticals Plc Licensing agreement with Orion for Easyhaler®
13 February 2017 - 8:19PM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
13 February 2017
PRESS RELEASE
Hikma announces exclusive licensing agreement with Orion for its
new Easyhaler(R) product in MENA
London, 13 February 2017 - Hikma Pharmaceuticals PLC (Hikma)
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing
multinational pharmaceutical group, today announces that it has
signed an exclusive licensing and distribution agreement with Orion
Corporation of Finland (Orion), for its new Easyhaler(R)
combination product, a dry powder inhaler (DPI) of budesonide and
formoterol, for the treatment of asthma and chronic obstructive
pulmonary disease (COPD).
Under the terms of the agreement, Hikma has the exclusive rights
to register, distribute, market and sell the product in all of its
MENA markets, leveraging Hikma's strong local presence, sales and
marketing capabilities and regulatory expertise.
Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging
Markets said, "We are pleased to be adding this important product
to our respiratory pipeline and we hope this collaboration with
Orion will be the beginning of a long partnership for its
Easyhaler(R) device products in the MENA region. Global
partnerships are an integral part of our strategy to grow our
portfolio in key therapeutic areas and improve patients' access to
high-quality medicines."
Markku Huhta-Koivisto, Senior Vice President of Orion's
Proprietary Products division, commented, "I am excited about this
collaboration between Orion and Hikma and look forward to having
such
a strong partner in the MENA region supporting the expansion of
our Easyhaler(R) business. This collaboration is also an excellent
opportunity to deepen our longstanding relationship with Hikma.
We're confident that the good momentum we have for our Easyhaler(R)
products will continue and that this partnership with Hikma will,
for its part, strengthen Orion's strategic objective to become a
stronger player in the field of respiratory medication."
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations +44
(0)20 7399 2760/ +44 7776 477050
Lucinda Baker, Deputy Director of Investor Relations +44 (0)20
7399 2765/ +44 7818 060211
FTI Consulting
Ben Atwell/ Matthew Cole +44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma operates through three businesses: "Injectables", "Branded"
and "Generics", based principally in the United States, the Middle
East and North Africa ("MENA") and Europe. In 2015, Hikma achieved
revenue of $1,440 million and profit attributable to shareholders
of $252 million. For more information visit www.hikma.com.
About Orion
Orion is a globally operating Finnish pharmaceutical company - a
builder of well-being. Orion develops, manufactures and markets
human and veterinary pharmaceuticals, active pharmaceutical
ingredients and diagnostic tests. The company is continuously
developing new drugs and treatment methods. The core therapy areas
of Orion's pharmaceutical R&D are central nervous system (CNS)
disorders, oncology and respiratory for which Orion develops
inhaled Easyhaler(R) pulmonary drugs. Orion's net sales in 2016
amounted to EUR 1,074 million and the company had about 3,500
employees. Orion's A and B shares are listed on Nasdaq Helsinki.
Founded in 1917, Orion celebrates its centennial anniversary in
2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAKXLBFDLFFBBZ
(END) Dow Jones Newswires
February 13, 2017 04:19 ET (09:19 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024